STOCK TITAN
  1. Home
  2. News
  3. RCUS

Arcus Biosciences, Inc. - RCUS STOCK NEWS

Welcome to our dedicated page for Arcus Biosciences news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.

Arcus Biosciences, Inc. (NASDAQ: RCUS) is a cutting-edge, clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment. Founded in 2015 by experienced researchers from the biotechnology and pharmaceutical sectors, Arcus is based in the San Francisco Bay Area, a hub for biotechnological innovation.

Arcus Biosciences focuses on leveraging insights in immunology to create new cancer therapeutics. The company is particularly known for its work on the ATP-adenosine pathway, a significant driver of immunosuppression in the tumor microenvironment. Their aim is to optimize small-molecule immuno-oncology product candidates that could revolutionize cancer treatment.

Arcus has a robust product pipeline that includes several promising candidates such as Domvanalimab, Etrumadenant, AB598, and Casdatifan. These drugs target different aspects of the immune system to either modulate cellular processes in cancer or directly combat tumor growth.

Significant achievements include successful clinical trials for treating various types of cancers, including lung, colorectal, and pancreatic cancers. The company operates through a single segment focused on the development and commercialization of its immunotherapies.

Arcus prides itself on maintaining an internal team of highly skilled professionals rather than outsourcing its research and development efforts. This approach ensures the highest quality and innovation in their drug discovery process.

With ongoing partnerships and collaborations, notably with Gilead Sciences, Arcus is well-positioned to bring its innovative therapies to market, providing new hope for patients with cancer.

News

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary
Arcus Biosciences (RCUS) will participate in investor conferences in March 2024, including Leerink Global Biopharma Conference and Barclays Global Healthcare Conference. The company aims to showcase its differentiated molecules and combination therapies for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
conferences
-
News

Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary
Arcus Biosciences, Inc. granted new employees options to purchase 17,600 shares of common stock and restricted stock units for 8,800 shares. The exercise price per share was $19.53, based on the closing price on February 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
none
-
News

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Rhea-AI Summary
Arcus Biosciences, Inc. and Gilead announce additional equity investment and modifications to clinical programs, with positive data supporting potential for casdatifan. Arcus reports financial results for Q4 2023, highlighting $1.2 billion in pro forma cash. The company plans six ongoing Phase 3 trials for three distinct programs and has cash runway into 2027. Key partnerships and pipeline updates are detailed in the PR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.87%
Tags
earnings
News

Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary
Arcus Biosciences, Inc. (RCUS) granted new employees options to purchase 71,900 shares at $15.20 per share and restricted stock units for 35,950 shares. The equity awards were granted under the 2020 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
none
-
News

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates

Rhea-AI Summary
Arcus Biosciences (NYSE:RCUS) will host a conference call and webcast to discuss pipeline updates and financial results for the quarter and year ended December 31st, 2023. The event will take place on February 21, 2024, at 2:00 PM PT / 5:00 PM ET. Investors can listen to the conference call by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free) using Access Code: 235272. The live webcast and slide presentation will be available on the company's website at www.arcusbio.com, with a replay available after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences earnings
-
News

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Rhea-AI Summary
Gilead Sciences, Inc. and Arcus Biosciences, Inc. have announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The investment reinforces the companies' conviction in the TIGIT pathway and provides an opportunity to accelerate the anti-TIGIT program. The amendment also provides Gilead with one additional seat on the Arcus Board. The press release highlights the governance enhancements enabling streamlined decision-making and reflects the continued growth of the collaboration. Gilead and Arcus have reprioritized the joint domvanalimab development program to focus on advancing and potentially accelerating the Phase 3 studies STAR-121 (lung cancer) and STAR-221 (gastrointestinal cancer). This prioritization reflects the companies' continued conviction in the TIGIT pathway and the Fc-silent design of domvanalimab, which has the potential for differentiation in both efficacy and safety. The additional investment by Gilead, which extends Arcus' cash runway into 2027, will enable the funding of Phase 3 studies of quemliclustat in pancreatic cancer and AB521 in kidney cancer, as well as the preparation for potential product approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
none
News

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Rhea-AI Summary
Gilead Sciences, Inc. invests $320 million in Arcus Biosciences, Inc. and amends collaboration agreement, raising Gilead's ownership stake in Arcus to 33%. The investment aims to accelerate the joint development programs, with a focus on advancing Phase 3 studies for lung and gastrointestinal cancers. The amendment also provides Gilead with one additional seat on the Arcus Board, enabling streamlined decision-making.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
none
-
News

Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary
Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of equity awards to new employees, including options to purchase 76,700 shares of common stock and restricted stock units for 38,350 shares. The exercise price per share was set at $15.26, based on the closing price on January 25, 2024. These awards were granted under the Company’s 2020 Inducement Plan, approved by the Board of Directors in January 2020.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
-
News

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Rhea-AI Summary
Arcus Biosciences, Inc. (RCUS) announced promising overall survival data from the ARC-8 Phase 1b study, showing a 37% reduction in the risk of death and a 5.9-month improvement in median overall survival for patients treated with quemliclustat-based regimens compared to chemotherapy alone. The study of quemliclustat plus chemotherapy with or without zimberelimab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) will be presented at the ASCO GI Symposium. The data shows a significant increase in survival compared to historical benchmark data for chemotherapy alone, with no observed clinically meaningful increase in toxicity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
clinical trial
News

Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary
Arcus Biosciences, Inc. (NYSE:RCUS) Grants Equity Awards to New Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none

FAQ

What is the current stock price of Arcus Biosciences (RCUS)?

The current stock price of Arcus Biosciences (RCUS) is $15.5 as of December 20, 2024.

What is the market cap of Arcus Biosciences (RCUS)?

The market cap of Arcus Biosciences (RCUS) is approximately 1.4B.

What does Arcus Biosciences, Inc. do?

Arcus Biosciences develops innovative immunotherapies for cancer treatment, focusing on the ATP-adenosine pathway.

Where is Arcus Biosciences located?

The company is based in the San Francisco Bay Area, a major center for biotechnology research.

When was Arcus Biosciences founded?

The company was founded in 2015 by a group of seasoned researchers.

What is the core focus of Arcus Biosciences' research?

Arcus focuses on developing small-molecule immuno-oncology product candidates that work on the ATP-adenosine pathway.

What are some of Arcus Biosciences' main products?

Their product pipeline includes Domvanalimab, Etrumadenant, AB598, and Casdatifan.

What types of cancer does Arcus Biosciences target?

The company conducts clinical trials for various cancers, including lung, colorectal, and pancreatic cancers.

Does Arcus Biosciences outsource its research and development?

No, Arcus prides itself on maintaining an internal team of skilled professionals for its R&D efforts.

With whom does Arcus Biosciences have significant partnerships?

Arcus has ongoing collaborations, notably with Gilead Sciences, to advance its research and bring therapies to market.

What makes Arcus Biosciences unique?

The company combines cutting-edge technology with innovative approaches to drug discovery, focusing on both small molecules and biologics.

What is the mission of Arcus Biosciences?

The mission is to create new cancer therapeutics through emerging insights in immunology, providing new hope for patients.

Stock RCUS logo
Arcus Biosciences, Inc.

NYSE:RCUS

RCUS Rankings

#2247 Ranked by Market Cap
N/A Ranked by Dividends

RCUS Stock Data

1.41B
54.37M
40.6%
60.08%
8.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAYWARD